Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker Novo Nordisk, confirmed that supply now meets or exceeds both the current ...